Rhode Island Hospital Comprehensive Cancer Center

Summary

Rhode Island Hospital Comprehensive Cancer Center is a medical facility located in Providence, Rhode Island. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Solid Tumors, Leukemia and other specialties. Rhode Island Hospital Comprehensive Cancer Center is involved with conducting 87 clinical trials across 132 conditions. There are 21 research doctors associated with this hospital, such as Jennifer J. Welch, Bradley DeNardo, Benedito Carneiro, and Adam J. Olszewski.

Top PIs

Clinical Trials running at Rhode Island Hospital Comprehensive Cancer Center

Cancer

Lung Cancer

Multiple Myeloma

Chronic Lymphocytic Leukemia

Breast Cancer

Melanoma

Relapse

B-Cell Leukemia

Non-Small Cell Lung Cancer

Leukemia

LY3537982 + Immunotherapy/Chemotherapy

for Non-Small Cell Lung Cancer

This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.

Recruiting

1 award

Phase 3

14 criteria

ABBV-CLS-484 + PD-1/VEGFR Inhibitors

for Cancer

The study will assess the safety, PK, PD, and preliminary efficacy of ABBVCLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). The trial aims to establish a safe, tolerable, and efficacious dose of ABBVCLS-484 as monotherapy and in combination. The study will be conducted in three parts. Part 1 Monotherapy Dose Escalation, Part 2 Combination Dose Escalation and Part 3 Dose Expansion (Monotherapy and Combination therapy). Part 1, ABBV-CLS-484 will be administered alone in escalating dose levels to eligible subjects who have advanced solid tumors. Part 2, ABBV-CLS-484 will be administered at escalating dose levels in combination with a PD-1 targeting agent or with a VEGFR TKI to eligible subjects who have advanced solid tumors. Part 3, ABBV-CLS-484 will be administered alone as a monotherapy at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC). ABBV-CLS-484 will also be administered at the determined recommended dose in combination with a PD-1 targeting or with a VEGFR TKI agent in subjects with locally advanced or metastatic, HNSCC, NSCLC, MSI-H tumors refractory to PD-1/PD-L1, and advanced ccRCC.

Recruiting

1 award

Phase 1

10 criteria

Multiple Drug Therapies

for Cancer in Children and Young Adults

This trial tests new cancer drugs to see if they help patients and how long the benefits last. It focuses on different types of cancer and adds new studies as new drugs are developed.

Recruiting

1 award

Phase 2